Ribociclib (Kisqali)
Other Medications · Approved since 2017
Description
Ribociclib is a selective cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor that blocks cell cycle progression from G1 to S phase. While primarily approved for hormone receptor-positive breast cancer, ribociclib is being explored in colorectal cancer through combination approaches with other targeted agents. In CRC, it is studied particularly in tumors with KRAS mutations as part of combination regimens with MEK inhibitors like trametinib.
Mechanism of Action
Ribociclib selectively inhibits cyclin-dependent kinases 4 and 6, which are key regulators of cell cycle progression. By blocking CDK4/6 activity, ribociclib prevents phosphorylation of the retinoblastoma protein, leading to cell cycle arrest in the G1 phase and ultimately inducing apoptosis in rapidly dividing cancer cells.
Molecular Targets
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
Quick Info
| Brand Name | Kisqali |
| Category | Other Medications |
 Status | Off-label |
 EMA Status | EMA Approved |
 Spain Access | Hospital use off-label in CRC |
| Administration | Oral |
| Year Approved | 2017 |
| Clinical Trials | 11 |
Related Medications
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.